SI1572167T1 - Transdermalni buprenorfinski dozirni reĹľim za analgezijo - Google Patents

Transdermalni buprenorfinski dozirni reĹľim za analgezijo

Info

Publication number
SI1572167T1
SI1572167T1 SI200331365T SI200331365T SI1572167T1 SI 1572167 T1 SI1572167 T1 SI 1572167T1 SI 200331365 T SI200331365 T SI 200331365T SI 200331365 T SI200331365 T SI 200331365T SI 1572167 T1 SI1572167 T1 SI 1572167T1
Authority
SI
Slovenia
Prior art keywords
buprenorphine
dosage form
dosage
analgesia
dosage regimen
Prior art date
Application number
SI200331365T
Other languages
English (en)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI1572167T1 publication Critical patent/SI1572167T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331365T 2002-12-13 2003-12-15 Transdermalni buprenorfinski dozirni reĹľim za analgezijo SI1572167T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia
EP03813444A EP1572167B1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Publications (1)

Publication Number Publication Date
SI1572167T1 true SI1572167T1 (sl) 2008-12-31

Family

ID=32595187

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331365T SI1572167T1 (sl) 2002-12-13 2003-12-15 Transdermalni buprenorfinski dozirni reĹľim za analgezijo

Country Status (16)

Country Link
US (1) US7270830B2 (sl)
EP (1) EP1572167B1 (sl)
JP (2) JP5054893B2 (sl)
AT (1) ATE400258T1 (sl)
AU (2) AU2003297073A1 (sl)
CA (1) CA2510223C (sl)
CY (1) CY1108384T1 (sl)
DE (1) DE60322102D1 (sl)
DK (1) DK1572167T3 (sl)
ES (1) ES2310262T3 (sl)
IL (1) IL169056A (sl)
MX (1) MXPA05006334A (sl)
NZ (1) NZ539936A (sl)
PT (1) PT1572167E (sl)
SI (1) SI1572167T1 (sl)
WO (1) WO2004054553A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
NZ539936A (en) * 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
ES2359977T3 (es) 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
MY141815A (en) * 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
PT1646328E (pt) 2003-07-25 2007-10-24 Euro Celtique Sa Tratamento da abstinência de dependência.
CA2529983C (en) * 2003-07-25 2010-07-20 Bruce E. Reidenberg Preoperative treatment of post operative pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
CA2845634C (en) 2011-08-18 2021-07-13 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
MX352795B (es) 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
GB2529789A (en) 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system
BR112018017167A2 (pt) * 2016-02-29 2019-01-02 Gruenenthal Gmbh titulação de cebranopadol
US20200187777A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
CA2062828C (en) * 1990-04-24 1996-04-16 Osafumi Hidaka Pharmaceutical plasters
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
NZ539936A (en) * 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
PT1646328E (pt) * 2003-07-25 2007-10-24 Euro Celtique Sa Tratamento da abstinência de dependência.

Also Published As

Publication number Publication date
AU2010201479B2 (en) 2012-11-01
CA2510223C (en) 2017-09-12
JP5054893B2 (ja) 2012-10-24
EP1572167A4 (en) 2007-01-10
CY1108384T1 (el) 2014-02-12
NZ539936A (en) 2007-06-29
PT1572167E (pt) 2008-10-03
DE60322102D1 (de) 2008-08-21
ATE400258T1 (de) 2008-07-15
CA2510223A1 (en) 2004-07-01
DK1572167T3 (da) 2008-10-13
AU2010201479A1 (en) 2010-05-06
JP2006513184A (ja) 2006-04-20
WO2004054553A1 (en) 2004-07-01
MXPA05006334A (es) 2005-08-26
EP1572167A1 (en) 2005-09-14
AU2003297073A1 (en) 2004-07-09
EP1572167B1 (en) 2008-07-09
WO2004054553A9 (en) 2005-09-15
US7270830B2 (en) 2007-09-18
ES2310262T3 (es) 2009-01-01
JP2010285457A (ja) 2010-12-24
IL169056A (en) 2012-01-31
US20040126416A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
SI1572167T1 (sl) Transdermalni buprenorfinski dozirni reĹľim za analgezijo
NO20060913L (no) Behandling av avhengighetsabstinens
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
HK1089106A1 (en) Fentanyl salt composition for nasal administration
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
MY119403A (en) Novel compounds with analgesic effect.
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
ATE433756T1 (de) Gelierte zusammensetzungen
DK1485051T3 (da) Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
NZ507203A (en) Use of dexmedetomidine for ICU sedation
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
NZ326345A (en) Composition containing diosgenin
GEP201606538B (en) Preoperative treatment of post operative pain
EP1011672A4 (en) CONNECTIONS WITH ANALGETIC EFFECT AND COMPILATIONS THAT CONTAIN THEM
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion
DE69814669D1 (de) Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
MX9804798A (es) Nuevos compuestos con efecto analgesico.
MX9804797A (es) Nuevos compuestos con efecto analgesico.
UA39418A (uk) Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori